ATL1103 Granted Orphan Drug Designation in Europe
Filed with ASX · · 2 pages · English
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- ATL1102 for Multiple Sclerosis - Update
- Antisense Technology Update
- Company Strategy Update
- Orphan Drug designation from FDA for ATL1103 in Acromegaly
- ATL1103 Higher Dose Study - Update
Later from Percheron Therapeutics
- Positive Results Achieved from ATL1103 Higher Dose Study
- Company Update
- ATL1103 Higher Dose Study
- Capital Management Initiatives - Update
- ATL1102 for Multiple Sclerosis - Progress Update
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics